March 07, 2025

New Clinical Guideline for Benzodiazepine Tapering Released

The new clinical practice guideline, developed in tandem by representatives from 10 medical societies, provides evidence-based and consensus recommendations for safe benzodiazepine tapering when risks outweigh benefits.

Conexiant

March 07, 2025

Novel Therapies Advance Psychiatric Treatment Options

New research has found intranasally administered esketamine's effects are short-lived. tDCS shows promise for depression, ondansetron has limited OCD impact, and Cobenfy enhances cognition in schizophrenia.

Conexiant

March 06, 2025

An Estimated 31 Million Americans Borrowed for Medical Bills in 2024

A new West Health-Gallup Survey survey reveals insights into medical debt across all income levels and demographics in the United States.

Conexiant

March 06, 2025

Toxic Stress Linked to Higher Cardiovascular Risk in Younger Women

Toxic stress was associated with an increased odds of cardiovascular disease among younger women but not older women, study shows.

Conexiant

March 04, 2025

Esketamine Efficacy Questioned 6 Years Following Approval

Analysis reveals "less is more" approach may be prudent for ketamine-derived depression treatment

Conexiant

February 28, 2025

Dementia Risk: Anticholinergic Bladder Drug Choice Key

Anticholinergic bladder drugs were associated with an increased risk of dementia compared with nonuse, but not when compared with the beta-3 agonist mirabegron.

Conexiant

February 26, 2025

New Medical Malpractice Rules Issued by American Law Institute

The American Law Institute's first restatement of medical malpractice law shifts focus from customary practice to evidence-based medicine.

Conexiant

February 24, 2025

Do Black Female Doctors Die Earlier?

New JAMA Internal Medicine study finds Black female physicians face higher mortality rates than White women in general population.

Conexiant

February 21, 2025

Examining Coprescription Trends Driving the Twin Epidemic

In a 10-year U.S. cohort study, researchers identified a strong association between stimulant coprescriptions and escalating opioid doses.

Conexiant